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Secreted phospholipase A2-IIA-induced a
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Abstract
Background: Activation of microglia, the primary component of the innate immune response in the brain, is a
hallmark of neuroinflammation in neurodegenerative disorders, including Alzheimer’s disease (AD) and other
pathological conditions such as stroke or CNS infection. In response to a variety of insults, microglial cells produce
high levels of inflammatory cytokines that are often involved in neuronal injury, and play an important role in
the recognition, engulfment, and clearance of apoptotic cells and/or invading microbes. Secreted phospholipase
A2-IIA (sPLA2-IIA), an enzyme that interacts with cells involved in the systemic immune/inflammatory response,
has been found up-regulated in the cerebrospinal fluid and brain of AD patients. However, despite several
approaches, its functions in mediating CNS inflammation remain unknown. In the present study, the role of
sPLA2-IIA was examined by investigating its direct effects on microglial cells.
Methods: Primary and immortalized microglial cells were stimulated by sPLA2-IIA in order to characterize the
cytokine-like actions of the phospholipase. The hallmarks of activated microglia analyzed include: mitogenic
response, phagocytic capabilities and induction of inflammatory mediators. In addition, we studied several of the
potential molecular mechanisms involved in those events.
Results: The direct exposure of microglial cells to sPLA2-IIA stimulated, in a time- and dose-dependent manner,
their phagocytic and proliferative capabilities. sPLA2-IIA also triggered the synthesis of the inflammatory proteins
COX-2 and TNFα. In addition, EGFR phosphorylation and shedding of the membrane-anchored heparin-binding
EGF-like growth factor (pro-HB-EGF) ectodomain, as well as a rapid activation/phosphorylation of the classical
survival proteins ERK, P70S6K and rS6 were induced upon sPLA2-IIA treatment. We further demonstrated that the
presence of an EGFR inhibitor (AG1478), a matrix metalloproteinase inhibitor (GM6001), an ADAM inhibitor (TAPI-1),
and a HB-EGF neutralizing antibody abrogated the phenotype of activated microglia induced by the sPLA2-IIA.
Conclusion: These results support the hypothesis that sPLA2-IIA may act as a potent modulator of microglial
functions through its ability to induce EGFR transactivation and HB-EGF release. Accordingly, pharmacological
modulation of EGFR might be a useful tool for treating neuroinflammatory diseases characterized by sPLA2-IIA
accumulation.
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Background
Microglial cells are considered as central nervous system
(CNS)-resident professional macrophages. They con-
stantly survey the brain parenchyma and react immedi-
ately to changes in the microenvironment, becoming
readily activated in response to infection or injury [1].
They may play a dual role, participating in host defense
of the brain and tissue repair, as well as acting as phago-
cytes to engulf tissue debris and dead cells. However,
microglia can also contribute to the establishment or
exacerbation of tissue damage depending on the type or
intensity of the harmful stimulus.
Cerebral ischemia and other neurodegenerative disor-
ders such as Alzheimer's disease (AD), Parkinson’s
disease, and multiple sclerosis, among others, are asso-
ciated with proliferation and activation of microglia
[2-6]. The activated microglia undergo dramatic mor-
phological changes, from a resting ramified form to an
activated amoeboid shape, and secrete a host of immu-
nomodulatory and neurotoxic factors. Whilst significant
advances have been made to identify the contribution
of the cytotoxic agents released from microglia to the
neurodegenerative process, it is less clear and remains to
be determined which factors trigger microglial activation
in these various disorders.
In neurodegenerative diseases such as Alzheimer’s, for
example, players involved in the inflammatory process
include S100a9, β-amyloid peptides (Aβ), macrophage
colony-stimulating factor and acute-phase proteins such
as C-reactive protein, amyloid P and secreted phos-
pholipase A2-IIA (sPLA2-IIA), among others [2,7-12].
Recent studies have revealed that S100a9, Aβ and
macrophage colony-stimulating factor themselves can
promote the reactivity of microglia to enhance their
neurotoxicity. However, any role that sPLA2-IIA might
play in microglia activation is still unknown.
Secreted phospholipases A2 represent a family of
eleven low molecular mass, calcium- dependent lipolytic
enzymes. They catalyze the hydrolysis of the sn-2 ester
bond of glycerophospholipids present in cell membranes
to form essential cell-signaling molecules. They are
widely distributed in human tissues including brain,
where their specific function is still largely unclear
[13,14], although current evidence suggests that sPLA2s
may affect some neuronal functions, such as neuritogen-
esis, neurotoxicity, neurotransmitter release and survival
[15-20]. Different levels of sPLA2 activity have been
found in various regions of the central nervous system
in both humans and rodents, and the subtypes identified
include sPLA2-IIA, IIC, IIE, II, V, X and XII.
Secreted PLA2-IIA (sPLA2-IIA) was first identified in
synovial fluid, and then characterized as an acute-phase
protein under the transcriptional control of pro-
inflammatory cytokine signaling [21]. Later on, its presence
in tears was reported and it came to be considered a
powerful innate ocular surface barrier against Gram-
positive bacteria [22]. Its serum levels dramatically increase
under pathological conditions that involve systemic inflam-
matory processes such as sepsis, rheumatoid arthritis, and
cardiovascular disease (up to 1000-fold and >1 μg/ml).
Additionally, enhanced expression of sPLA2-IIA has also
been found in certain neurological disorders and as a result
of brain insult, it being associated with CNS injuries such
as cerebral ischemia or mechanical damage to spinal cord
tissue [18,23-26]. Recent reports have shown it to be up-
regulated in both cerebrospinal fluid and brain of patients
with Alzheimer’s disease. In fact, increased immunoreactiv-
ity for sPLA2-IIA has been reported in reactive astrocytes
of the cortex and hippocampus (restricted mainly to the
dentate gyrus and CA3 field) around Aβ-containing pla-
ques [11,12].
sPLA2-IIA, as well as other sPLA2 subtypes, can also
exert various biological functions and transduce signals
independently of their catalytic activity through recep-
tors or binding proteins such as M-type receptor, factor
Xa, integrin αvβ3 and α4β1, heparan sulfate and proteo-
glycans, etcetera [27-31]. Indeed, it has been reported
that sPLA2-IIA influences survival of some cellular types
within the CNS including oligodendrocytes and neurons,
independently of its catalytic activity [19,24].
In this study, we provide data demonstrating the func-
tional consequences of microglial cell exposure to the
activating agent sPLA2-IIA. We have measured prolifera-
tive responses, phagocytic capabilities and synthesis
and release of several molecules with pro-inflammatory
activities, for example, tumor necrosis factor-α (TNFα)
and cycloxigenase-2 (COX-2), as indices of microglial
activation. In addition, we have characterized several of the
potential molecular mechanisms involved in these events.
Methods
Reagents
A C127 mouse fibroblast cell line, stably transfected with
the coding sequence of sPLA2-IIA from human placenta,
was kindly provided by Dr Olivier (Nancy University Hos-
pital, Nancy Cedex, France) and used as a source of human
recombinant enzyme (hr-sPLA2-IIA) in some experiments
to ascertain specificity [32]. sPLA2-IIA was obtained and
purified as described previously [33]. The absence of lipo-
polysaccharide (LPS) in the preparation was confirmed by
the limulus amebocyte lysate assay test in the batches used
for the experiments. Moreover, experiments are conducted
in the absence of fetal calf serum (FCS), which ensures that
the effect is observed in the absence of LPS binding protein,
necessary for the action of low concentrations of LPS.
Bee venom sPLA2-III (structurally related to human
group III) and human recombinant sPLA2-V were
from Cayman (Tallinn, Estonia). Rapamycin, pyrazole
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pyrimidine-type 2 (PP2), porcine sPLA2-IB, LPS, both
anti-rabbit and anti-mouse fluorescein isothiocyanate
(FITC) secondary antibodies, FITC-dextran and other
chemicals were from Sigma Chemical Co. (St. Louis,
MO, USA.). PD98059 and AG1478 inhibitors were from
Tocris Biosciece (Bristol, UK). Policlonal anti-heparin-
binding epidermal growth factor (HB-EGF) neutralizing
antibody and the inhibitors GM6001, chloromethylke-
tone (CMK) and TNFα proteinase inhibitor-1 (TAPI-1)
were from Calbiochem (San Diego, CA, USA). Rabbit
anti-mitogen-activated protein kinase (MAPK) was from
Zymed Laboratories (San Francisco, CA, USA). Rabbit
antibody phosphorylated (phospho)-ERK1/2 (Thr202/
Tyr204), phospho-S6 ribosomal protein (Ser235/236)
and phospho-P70S6 kinase (Thr389) were from Cell
Signaling Technology, Inc. (Danvers, MA, USA). The
Rabbit phosphor-Src (Ser473), phospho-EGF (Tyr1173),
phospho-EGF (Tyr845), anti-actin, and COX-2 anti-
bodies were from Santa Cruz Biotechnology Inc. (Santa
Cruz, CA, USA). Hybond-P membrane was from
Amersham Biosciences (GE Healthcare Europe GmbH,
Barcelona, Spain). DMEM and the cell culture supple-
ments, including FCS, were purchased from Gibco BRL
(Burlington, Canada).
Cell culture
BV-2 murine microglia cells, a generous gift from Dr JR
Bethea (University of Miami School of Medicine, Miami,
Florida, USA), were cultured at 37°C in a humidified
atmosphere of 5% CO2 in high sucrose DMEM, supple-
mented with 100U/ml penicillin, 100 μg/ml strepto-
mycin, 50 μg/ml gentamicin, 2 mM glutamine, and 10%
heat-inactivated fetal calf serum (FCS).
Primary microglia-enriched cultures were obtained
from primary mixed glial cultures from 2- to 4-day-old
neonatal C57BL/6 mice. To obtain mixed glial cultures,
cerebral cortices were dissected, carefully stripped of
their meninges, and digested with 0.25% trypsin-EDTA
solution (Invitrogen, Life Technologies S.A., Madrid,
Spain) for 25 minutes at 37°C. Trypsinization was
stopped by adding an equal volume of culture medium,
to which 0.02% deoxyribonuclease I (Sigma) was added.
The culture medium consisted of DMEM-F-12 nutrient
mixture supplemented with 10% FCS, 0.1% penicillin-
streptomycin, and 0.5 μg/mL amphotericin B (Fungi-
zone, Invitrogen). Cells were pelleted (5 minutes, 200 g),
re-suspended in culture medium, and brought to a single
cell suspension by repeated pipetting followed by passing
through a 105 μm-pore mesh. Cells were seeded at a
density of 3.5 × 105 cells/ml (1.2 × 105 cells/cm2) and
cultured at 37°C in a 5% CO2 humidified atmosphere.
Medium was replaced every 5 to 7 days. Microglial cul-
tures were prepared by the mild trypsinization method
previously described by Saura et al. [34]. Briefly, after
19 to 21 days in vitro, mixed glial cultures were treated
for 30 minutes with 0.06% trypsin in the presence of
0.25 mM EDTA and 0.5 mM Ca2+. This resulted in the
detachment of an intact layer of cells containing virtually
all the astrocytes, leaving a population of firmly attached
cells identified as> 98% microglia. The microglial cul-
tures were treated 24 h after isolation by this procedure.
Experiments were carried out in accordance with the
Guidelines of the European Union Council (86/609/EU),
following the Spanish regulations (BOE 67/8509-12, 1988)
for the use of laboratory animals, and approved by the
Animal Ethics Committee of the Universidad de Valladolid.
Cultures were found to be 99% microglia by staining with
FITC-conjugated Griffonia (Bandeiraea) simplicifolia lectin
I-B4 isolectin (1:100, Sigma St. Louis, MO, USA), a lectin
that recognizes microglia, and an antibody against glial fi-
brillary acidic protein (Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA), to identify astrocytes.
Primary and immortalized microglial cells were
serum-starved 24 h before the experiments, and then
were stimulated for different times, as indicated, in the
presence or absence of inhibitors.
Proliferation assay
Cell proliferation was quantified using the Promega kit,
Cell Titer 96RAqueous One Solution Cell Proliferation
Assay (Promega Corporation, Madison, Wisconsin, USA,
according to the manufacturer's recommendations.
Briefly, primary and immortalized BV-2 microglial cells
were seeded in 96-well tissue culture plates and serum-
starved for 24 h. Then, cells were treated in quadruplicate
with the stimuli, in the presence or absence of the indi-
cated inhibitors. After 24 h of incubation, formazan prod-
uct formation was assayed by recording the absorbance at
490 nm in a 96-well plate reader. The results were
expressed as optical density (OD) values, as an assessment
of the number of metabolically active cells. Microglia cell
viability was also assessed by trypan blue exclusion.
Western blot analysis
After treatment, cells were washed twice with PBS and har-
vested in Laemmli SDS sample buffer. Protein extracts were
separated by SDS-PAGE and transferred to polyvinylidene
difluoride membranes, which were incubated for 18 h at
4°C with the indicated antibodies, including ERK 1/2, p-
ERK1/2, p-P70S6K, p-rS6, COX-2 and actin. After washing
with Tris-Tween buffered saline (TTBS), a 1:2.000 (v/v) di-
lution of horseradish peroxidase-labeled immunoglobulin
(IgG) was added at room temperature for 30 h. The blots
were developed using enhanced chemiluminescence.
Flow cytometric analysis
BV-2 cells, 5 × 106/flask, were treated with 1 μg/ml of
sPLA2-IIA for different periods of time at 37°C. Cells to
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be analyzed for expression of epidermal growth factor
receptor (EGFR) were fixed in a mixture of 4% parafor-
maldehyde and 0.2% Triton X-100 in PBS for 15 minutes
at room temperature, before incubation with FITC-
conjugated anti-mouse EGFR antibody for 1 h at 4°C, as
previously described [35]. For EGFR phosphorylation
analysis, cells were fixed in 4% paraformaldehyde for
15 minutes, washed with PBS, permeabilizaed with 0.3%
Triton X-100 for 5 minutes, washed, incubated with
anti-phospho EGFR (Tyr1173) or EGFR (Tyr845) anti-
body for 1 h at 4°C, and then with an FITC-labelled sec-
ondary antibody for 45 min at 4°C. After washing, the
cells were analyzed with a Flow Cytometer (GalliosTM;
Beckman Coulter, Brea, CA, USA). Data analysis was
performed using WinMDI 2.7 software (Scripps Institute,
La Jolla, CA, USA).
Induction of apoptosis
Jurkat T cells were cultured in RPMI 1640 with 10% FBS
at 37°C in 5% CO2. Apoptosis was induced in Jurkat T
cells (106 cells/ml) by overnight exposure to 400 μM
H2O2 in serum-free RPMI medium. To distinguish
between cells in the early or late stages of apoptosis,
staining with Annexin V-FITC was combined with pro-
pidium iodide (PrI) staining. Afterwards, cells were
immediately analyzed by flow cytometry (GalliosTM;
Beckman Coulter, USA). Cells in the early stage of apop-
tosis were negative for PrI but stained with Annexin V-
FITC, whereas in the late stage apoptotic cells stained
for both PrI and Annexin V-FITC. Jurkat T cells treated
in this way were about 90% late-stage apoptotic cells.
Phagocytosis assays
Phagocytosis of particles
Microglial cells seeded in 96-well plates or in 25-mm2
flasks were incubated with medium, 1 μg/ml of sPLA2-
IIA, 100 UI/ml of interferon-γ (IFNγ) at 37°C for 24 h,
in the presence or absence of the indicated inhibitors.
After 24 h, the phagocytic ability of the cells was mea-
sured using FITC-dextran as a tracer [36]. Briefly, cells
were exposed to 0.1 mg/ml of FITC-labelled dextran
(MW 40,000) for 2 h. Non-internalized particles were
removed by vigorously washing three times with cold
PBS (pH 7.4) prior to measuring fluorescence at 480 nm
excitation and 520 nm emission on either a Flow Cyt-
ometer (GalliosTM; Beckman Coulter, USA) or a Fluoros-
kan multiwell plate reader (TECAN Genios Pro; Tecan
Group Ltd, Männedorf, Switzerland). As a background,
the cultures without FITC-dextran were used (blank
wells). Each culture condition was performed in quadru-
plicate, and three independent experiments were per-
formed. To visualize the internalized dextran, cells were
also analyzed on a Leica TCS SP5X confocal microscope
with a ×60 oil objective.
Phagocytosis of apoptotic cells (efferocytosis)
Phagocytic assays were performed on BV-2 cells (effector
cells) after 24 h incubation in the presence of the inflam-
matory stimuli. Apoptotic Jurkat T cells were used as
target cells. Briefly, PrI-labeled apoptotic Jurkat T cells
were added to the BV-2 cells at a 8 to 10:1 ratio (apop-
totic cell to BV-2) and incubated at 37°C in 5% CO2 for
2 h in DMEM medium. Then, BV-2 cells were washed
gently with cold PBS and trypsinized by incubating them
with a solution 0.25% trypsin/EDTA for 5 minutes to
remove uningested cells. Afterwards, cells were fixed,
stained with a PE-conjugated-CD68 antibody and ana-
lyzed by flow cytometry. PE fluorescence was analyzed
in FL2 (555 to 600 nm), while red fluorescence from PrI
was analyzed in FL3 (555 to 600 nm). To quantify
phagocytosis, PrI fluorescence was analyzed only in the
cell populations exhibiting PE-CD68 positive staining
(BV-2 microglia cells). The BV-2 microglia cells were
positive for PrI fluorescence only if they had ingested
PrI-labeled Jurkat T cells. To confirm efferocytosis, a
Leica TCS SP5X confocal microscope was used with the
Leica LAS AF acquisition software and a ×60 oil object-
ive. For confocal microscopy, BV-2 cells were plated
onto 12-mm round cover slips and stained with an
Alexa-fluor-CD11b antibody. We used 4',6'-diamidino-2-
phenylindole hydrochloride (DAPI) to identify nuclei in
BV-2 cells.
Statistical analysis
All data were expressed as the mean ± SD and analyzed
by one-way ANOVA followed by post-hoc comparisons
(Bonferroni test) using the GraphPad Prism Version 4
software (San Diego, CA, USA). P< 0.05 was considered
statistically significant.
Results
sPLA2-IIA triggers microglial proliferation
A great deal of attention has recently focused on the
cytokine-like actions of sPLA2-IIA and its input to
inflammation-associated diseases. Having been found
highly expressed in several CNS pathological conditions,
we hypothesized that sPLA2-IIA might act as a cytokine-
like modulator on brain-resident immune cells. To test
this possibility, we examined whether sPLA2-IIA could
induce some of the hallmarks of activated microglia. We
used the immortalized mouse microglial cell line BV-2
as an in vitro model to mimic the microglial activation
observed in neurodegenerative disorders — such cells
have been proven to reproduce the behavior of primary
microglia and do not express endogenous sPLA2-IIA
[14,37-39]. Serum-starved BV-2 cells were stimulated for
24 h with the indicated concentrations of sPLA2-IIA,
and its effect on the proliferative activity of the cells was
evaluated with a colorimetric assay. Our results revealed
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that sPLA2-IIA markedly stimulated cell proliferation in
a dose-dependent manner and reached a 3-fold increase
(P< 0.001) when stimulated with 0.5 μg/ml of sPLA2-
IIA, as compared with unstimulated cells (Figure 1A).
The dose inducing the maximal change, 1 μg/ml, was
used for all subsequent experiments. We also found a
strong mitogenic response to other secreted PLA2s
(1 μg/ml), as well as to the well known inducer/amplifier
of microglia pro-inflammatory functions, IFNγ (100 UI/
ml) (Figure 1B). Furthermore, as shown in Figure 1C,
primary microglial cultures also responded to the
addition of sPLA2-IIA and IFNγ with a modest but
significant (P< 0.001) increase in cell proliferation
(Figure 1C).
This effect on growth was paralleled by the activation/
phosphorylation of key proteins involved in cell survival
and proliferation such as ERK, P70S6K and rS6. Acti-
vated forms of these proteins from whole cell lysates
were monitored using specific anti-phospho antibodies
that recognize only their activated/phosphorylated form.
To determine whether the mTORC1 pathway was
activated following sPLA2-IIA stimulation, we used an
antibody that detects phosphorylation of P70S6K on
threonine 389, a site well known to be selectively phos-
phorylated by mTORC1 and widely used to monitor
mTORC1 activation.
As shown in Figure 1D, sPLA2-IIA treatment induced
a rapid and sustained increase in ERK, P70S6K and rS6
phosphorylation in BV-2 cells. This effect was blocked
in the presence of specific pharmacological inhibitors,
including PD98059 (MEK inhibitor), rapamicin (mTOR
inhibitor) and PP2 (Src kinase inhibitor), which also
affected the proliferative response (Figure 1E, F). Thus,
ERK and mTORC1 are key components of the intra-
cellular signals regulating cell growth.
Involvement of epidermal growth factor receptor (EGFR)
transactivation in sPLA2-IIA-enhanced microglial cell
proliferation
Next, we analyzed whether sPLA2-IIA-induced cell pro-
liferation involves EGFR signaling, since transactivation
of this receptor is a crucial signaling mechanism for con-
trolling cell survival, migration and proliferation. Func-
tional expression of EGFR in microglial cells has been
previously described [40], and a flow cytometry analysis
revealed that resting BV-2 cells also constitutively
express it (Figure 2A). After that, we investigated
whether sPLA2-IIA treatment caused tyrosine phosphor-
ylation of EGFR at Tyr-845, as well as at Tyr-1173
(a major autophosphorylation site), by using anti-
phospho-specific antibodies and flow cytometry analysis.
As shown in Figure 2B.a, a rapid and sustained phos-
phorylation of EGFR at both Tyr-1173 and Tyr-845 was
detected in BV-2 cells upon phospholipase stimulation.
Phosphorylation of Tyr-845 is believed to stabilize the
receptor activation loop and is required for the mito-
genic function of the receptor, whereas phosphorylation
of Tyr-1173 is involved in MAPK activation. In addition,
EGFR phosphorylation in response to sPLA2-IIA was
similar in extent to that observed in response to EGF
(used as a positive control). Studies on primary micro-
glial cells also showed EGFR phospharylation at Tyr-
1173 upon sPLA2-IIA treatment (Figure 2C). These
results indicate that sPLA2-IIA is able to cause transacti-
vation of EGFR in microglial cells.
Next, to determine whether EGFR transactivation is
required for sPLA2-IIA-induced mitogenic signals, we
pre-incubated primary and immortalized BV-2 cells in
the presence of different doses of the selective EGFR
tyrosine kinase inhibitor, AG1478. We found that the
presence of the inhibitor diminished the proliferative
response induced by 24 h of phospholipase stimulation
(Figure 3A, B) in a dose-dependent manner. The activa-
tion and phosphorylation of the key signaling proteins
ERK, P70S6K and rS6 (Figure 3C), as well as EGFR
phospholylation at Tyr-1173 (Figure 3D) was fully abol-
ished in AG1478-pretreated BV-2 cells. The presence of
AG1478 only partially suppressed phosphorylation of
Tyr-845 (data not shown). These findings demonstrate
that EGFR transactivation accounted for sPLA2-IIA-
promoted cell proliferation and intracellular signaling
in microglial cells, and suggest that EGFR phosphor-
ylation initiated by sPLA2-IIA requires its intrinsic kin-
ase activity.
Several lines of evidence have suggested that transacti-
vation of EGFR may be mediated via metalloproteinases
(MMP) by extracellular release of EGFR ligands, such as
transforming growth factor (TGF), amphiregulin and
heparin-binding EGF-like growth factor (HB-EGF), from
the cell membrane. To identify the potential underlying
mechanisms linking sPLA2-IIA-induced proliferation
and EGFR transactivation, microglia cells were then pre-
incubated for 30 minutes with either the general matrix
metalloproteinase inhibitor GM6001 (commonly used to
inhibit ectodomain shedding), the disintegrin and metal-
loproteinase domain (ADAM) inhibitor, TAPI-1 (TNF-α
proteinase inhibitor-1) or the furin inhibitor CMK (uti-
lized to block ADAM zymogens activation), and then
challenged with 1 μg/ml of sPLA2-IIA for 24 h. As
shown in Figure 4A, the mitogenic ability of the sPLA2-
IIA was significant reduced, or even abolished, in the
presence of the mentioned inhibitors. Subsequently, we
examined the effect of these inhibitors on the phosphor-
ylation of ERK, P70S6K and rS6 proteins. As shown in
Figure 4B.a,b,c, pre-treatment of cells with these inhibi-
tors completely blocked the sPLA2-IIA effect on the
phosphorylation of the studied proteins. In addition, by
flow cytometry analysis, we also found that the presence
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Figure 1 sPLA2-IIA modulates proliferation in microglial cells. BV-2 cells were stimulated with different doses of sPLA2-IIA and 10% of FCS
(A), or with the indicated stimuli (B). Primary microglial cells were stimulated with 1 μg/ml of sPLA2-IIA or 100 UI/ml of IFNγ (C). After 24 h of
incubation at 37°C, cell proliferation was investigated and expressed as optical density (OD) values ± SD. Values are the average of three separate
experiments in quadruplicate (*P< 0.001 vs. control cells). (D) BV-2 microglial cells were incubated with sPLA2-IIA for different times. Cell lysates
were collected and subjected to western blot analysis using Abs against p-Src, ERK 1/2, p-ERK1/2, p-P70S6K, p-rS6 and actin. (E) BV-2 cells were
treated at 37°C for 30 minutes in the presence or absence of the indicated inhibitors, and then were stimulated with 1 μg/ml of sPLA2-IIA. After
24 h of incubation, cell proliferation was investigated and expressed as OD values ± SD. Values are the average of three separate experiments in
quadruplicate (*P< 0.001 vs. control cells, **P< 0.001 vs. sPLA2-IIA-treated cells). (F) BV-2 cells were treated as in (D). After 15 minutes stimulation,
whole cell lysates were extracted and protein phosphorylation was assessed by western blotting using p-ERK, p-P70S6 and p-rS6 antibodies.
Membranes were always stained with Ponceau S as a loading control.
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Figure 2 sPLA2-IIA induces epidermal growth factor receptor (EGFR) transactivation in microglial cells. (A) EGFR expression on untreated
BV-2 cells was analyzed by flow cytometry (open black curves) and compared with isotype controls (solid grey curves). (B) Flow cytometry
analysis of phospho-EGFR levels: a) BV-2 cells were untreated (solid black curves) or treated with 1 μg/ml of sPLA2-IIA (solid dark grey curves)
for different times; b) BV-2 cells were untreated (open black curves), treated with 1 μg/ml of sPLA2-IIA (open dark grey curves), or treated with
0.4 μM of EGF (open green curves) for 15 minutes, and compared with isotype controls (solid light grey curves). (C) Flow cytometry analysis of
phospho-EGFR levels in primary microglial cells. Cells untreated (open black curves) and treated with 1 μg/ml of sPLA2-IIA for 15 (open dark grey
curves). Solid light grey curves show negative controls in which the primary antibody was omitted. Results shown are representative of three
independent experiments.
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of GM6001 and TAPI-1 successfully reduced the EGFR
phosphorylation triggered by sPLA2-IIA (Figure 4C).
Interestingly, pre-treatment with the selective inhibitors
PD98059 (25 μM) and rapamycin (50 nM), did not affect
EGFR phosphorylation induced by sPLA2-IIA, whereas
it was fully prevented by the presence of Src kinase
inhibitor, PP2 (10 μM) (data not shown), suggesting that
EGFR phosphorylation can occur by multiple mechan-
isms. We also used the highly selective inhibitor of
MEK1/2, U0126, and we found that while ERK phos-
phorylation induced by sPLA2-IIA was completely abol-
ished by the presence of 5 and 10 μM of U0126,
phosphorylation of EGFR both at Tyr1173 and at 845
was not affected (data not shown). These results also
imply that ERK and mTOR pathways are downstream
targets of EGFR signaling.
sPLA2-IIA induces a proliferative response in microglial
cells via an epidermal growth factor receptor (EGFR)-
ligand-dependent mechanism
Among the various EGFR ligands that could be pro-
cessed by proteolysis, we focused on HB-EGF, because it
is both a leading molecule linked to ligand shedding and
EGFR transactivation, and pro-HB-EGF is a target of
ADAMs enzymes. To determine whether HB-EGF con-
tributes to sPLA2-IIA-induced cell growth and signaling
in BV-2 cells, we first examined its cell surface expression
by flow cytometry analysis using an ectodomain-specific
antibody. As shown in Figure 5A, BV-2 microglial cells
constitutively express pro-HB-EGF and their stimulation
with 1 μg/ml of sPLA2-IIA results in a rapid 5-minute re-
duction of its levels in the cell surface. This reduction
in cell surface content of endogenous pro-HB-EGF,
while completely unaffected by the presence of AG1478
(2.5 μM), was fully prevented by pre-treating the cells
with the non-selective metalloproteinase inhibitor
GM6001 (50 μM) or the ADAMs inhibitor TAPI-1
(10 μM), pointing to an ADAMs-mediated mechanism by
which sPLA2-IIA-treatment might cause the shedding of
pro-HB-EGF on BV-2 cells. In addition, inhibition of the
ERK and mTOR pathways with PD98059 or rapamicyn,
respectively, did not alter the pro-HB-EGF cell surface
expression levels of sPLA2-IIA-stimulated cells. In contrast,
the presence of the Src kinase inhibitior PP2 completely
blocked sPLA2-IIA-induced HB-EGF release. Next, we
examined the contribution of HB-EGF shedding to
Figure 3 sPLA2-IIA-induced proliferation in microglial cells is dependent on epidermal growth factor receptor (EGFR) transactivation.
(A, B) Primary and immortalized BV-2 microglial cells were stimulated with 1 μg/ml of sPLA2-IIA in the absence or presence of AG1478 at 37°C.
After 24 h, cell proliferation was investigated and expressed as optical density values ± SD. Values are the average of three separate experiments
in quadruplicate (*P< 0.001 vs. control cells, **P< 0.001 vs. sPLA2-IIA-treated cells). (C) After 15 minutes, ERK 1/2, P70S6 and rS6 phosphorylation
were identified in the cell lysates of BV-2 microglial cells by western blot. Membranes were stained with Ponceau S as a loading control. (D) BV-2
cells were stimulated with 1 μg/ml of sPLA2-IIA in the absence or presence of 2.5 μM of AG1478 for 15 minutes. Flow cytometry analysis of
phospho-EGFR levels in untreated (open black lines), sPLA2-IIA-treated (open dark grey lines) and AG1478+ sPLA2-IIA-treated (open blue lines)
cells. Solid light grey curves show negative controls in which the primary antibody was omitted. Results shown are representative of three
independent experiments.
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sPLA2-IIA-indued EGFR transactivation and signaling by
pre-incubating the cells for 30 minutes with a polyclonal
anti-HB-EGF neutralizing antibody, which prevents bind-
ing of HB-EGF to the extracellular domain of the EGFR.
As shown in Figure 5B and C, the presence of the neu-
tralizing antibody completely prevented sPLA2-IIA-
induced tyrosine phosphorylation of EGFR, ERK, P70S6K
and rS6. Moreover, we found that the presence of
the neutralizing antibody abrogated the ability of the
phospholipase to enhance primary and immortalized BV-
2 cell proliferation (Figure 5D and E). Interestingly, IFNγ
induced a mitogenic response in BV-2 cells that was also
HB-EGF-dependent. These data support the hypothesis
that the EGFR pro-ligand HB-EGF is required for sPLA2-
IIA to stimulate cell growth, and for activation of key
intracellular signaling pathways.
sPLA2-IIA treatment enhances phagocytosis and
efferocytosis in BV-2 microglia cells
To determine whether sPLA2-IIA-induced changes in
growth are extended to other functional aspects of
microglia, we studied the effect of sPLA2-IIA on the
phagocytic capacity of BV-2 cells. Microglial cells were
exposed to sPLA2-IIA for 24 h, and phagocytosis assays
were carried out by incubating activated microglial cells
with either FITC-labeled dextran beads (as measures of
non-specific phagoytosis) or apoptotic Jurkat cells (as
measures of disease-relevant processes of phagocytosis).
To quantify phagocytosis of fluorescent particles/cells a
flow cytometer and a microplate fluorescence reader
were used. IFNγ-treated BV-2 cells were taken as the
positive control in the above experiment. As shown in
Figure 6A and F, cell stimulation with both sPLA2-IIA
and IFNγ enhanced phagocytic function in both primary
and immortalized BV-2 microglial cells. In a parallel set
of experiments, the effect of sPLA2-IIA at the optimal
dose of 1 μg/ml was compared with that of other
secreted phospholipase A2 isoforms: sPLA2-III, -IB or -V,
to clarify whether the action of sPLA2-IIA on microglial
phagocytosis is a general property of the sPLA2 family.
As shown in Figure 6B, we found that all tested phos-
pholipases had a similar stimulatory effect on promoting
microglial phagocytosis of dextran beads. To further
confirm their internalization, confocal microscopy was
used (Figure 6C). Representative confocal fluorescence
images clearly demonstrated that the fluorescent dextran
beads were taken up into the cytoplasm of BV-2 micro-
glial cells. We also evaluated the uptake of FITC-labeled
dextran beads using flow cytometry analysis (Figure 6D).
Both sPLA2-IIA- and IFNγ-treated BV-2 cells showed
higher intracellular levels of the labeled dextran beads in
comparison to untreated cells. Interestingly, the presence
of inhibitors targeting specific upstream and down-
stream signaling mediators of EGFR transactivation effi-
ciently suppressed the phagocytic response induced by
sPLA2-IIA (Figure 6E). Similar results were obtained in
mouse primary microglia cells (Figure 6G).
Next, we investigated the potential for BV-2 cells to
engulf apoptotic cells (efferocytosis) and the effect of
sPLA2-IIA in this system (Figure 7). As described in
Methods, apoptotic Jurkat T cells were loaded with PrI
to visualize engulfed T cells within microglial cells, and
BV-2 cells were immunostained with CD68-PE. Jurkat T
cells were treated for 18 h with 400 μM of H2O2 and
apoptosis was confirmed by an annexin-V assay (data
not shown). Apoptotic Jurkat T cells were then added to
a culture of BV-2 cells-treated under different conditions
with a ratio of Jurkat to BV-2 cells of 8:1. After 2 h incu-
bation, the co-culture was analyzed by flow cytometry
to quantify cell uptake. As shown in Figure 7A, we
observed very little phagocytosis under control condi-
tions where BV-2 cells were resting. However Jurkat en-
gulfment increased significantly when BV-2 cells were
pre-treated for 24 h with 1 μg/ml of sPLA2-IIA or 100
UI/ml of IFNγ, as increasing number of microglia cells
showed FL3-fluorescence-positive signals. In a separate
experiment, the cells were also stained with DAPI and
studied using a confocal microscope to visually confirm
the ingestion of apoptotic cells (Figure 7B). The orthog-
onal reconstruction images showed the spatial relation
of ingested cells to the BV-2 cell nucleus (Figure 7C)
and confirm that Jurkat cells were not merely bound to
the cell surface.
In subsequent experiments, we examined whether
transactivation of EGFR is also a key step for controlling
sPLA2-IIA-mediated efferocytosis. Consistent with the
signaling mechanism recruited by the secreted phospho-
lipase to promote proliferation of BV-2, we found that
(See figure on previous page.)
Figure 4 Matrix metalloproteinases inhibitors modulate the proliferative response induced by sPLA2-IIA in BV-2 cells. BV-2 cells were
treated for 30 minutes at 37°C in the presence or absence of the indicated inhibitors, and then were stimulated with 1 μg/ml of sPLA2-IIA.
(A) After 24 h, cell proliferation was investigated and expressed as optical density. values ± SD. Values are the average of three separate
experiments in quadruplicate (*P< 0.001 compared to control cells, **P< 0.001 compared to sPLA2-IIA-treated cells). (B) After 15 minutes, ERK
1/2, P70S6 and rS6 phosphorylation were identified in the cell lysates by western blot. Membranes were stained with Ponceau S as a loading
control. (C) Phosphorylation levels of EGFR on untreated (open black curves), 1 μg/ml of sPLA2-IIA-treated (open dark grey curves), and MMP
inhibitors + 1 μg/ml of sPLA2-IIA-treated (open blue curves) BV-2 cells were analyzed by flow cytometry and compared with isotype controls
(solid grey curves). Results shown are representative of three independent experiments.
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the presence of the selective inhibitors GM6001, CMK
and TAPI-1 also abolished the phagocytic response trig-
gered by the sPLA2-IIA on microglial cells (Figure 6D),
as it previously did on sPLA2-IIA-enhanced cell growth.
sPLA2-IIA promotes synthesis and secretion of
inflammatory mediators in BV-2 cells
Finally, we examined whether sPLA2-IIA could affect
the expression levels of pro-inflammatory mediators in
Figure 5 (See legend on next page.)
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BV-2 microglia cells. Then, BV-2 cells were treated with
the optimal concentration of 1 μg/ml of sPLA2-IIA or
100 UI/ml of IFNγ for 4 and 8 h, and the expression of
COX-2 was examined in the cell lysate by western blot.
Our results revealed that both treatments markedly
induced the expression of the pro-inflammatory protein
COX-2 (Figure 8A). We also measured the production
of the cytokine TNFα using a commercial ELISA assay.
We observed that in the supernatant of cells treated with
sPLA2-IIA or IFNγ for 24 h, the levels of TNFα were
significantly enhanced, compared with untreated cells
which did not produce TNFα spontaneously (Figure 8B).
In contrast, the release or accumulation of anti-
inflammatory mediators, such as IL-10 was not detected
in any of our culture conditions (data not shown).
Lastly, we further examined whether blockage of EGFR
signaling at different levels, as demonstrated in previous
sections, affects the expression of these inflammatory
proteins induced by sPLA2-IIA. Figure 8C and D show
that sPLA2-IIA-induced up-regulation of COX-2 and
secretion of TNFα was significantly inhibited by the
presence of the inhibitors AG1478, GM6001, TAPI-1
and CMK, as well as by the polyclonal anti-HB-EGF
antibody. Similarly, IFNγ-induced COX-2 expression
was also abrogated by the presence of the neutralizing
anti-HB-EGF antibody.
All these studies clearly pointed to a crucial role of
EGFR transactivation, through MMP-mediated cleavage
of mature forms of EGFR ligands, in the signaling and
functional activity of the sPLA2-IIA.
Discussion
Microglia, the major cellular source and target of inflam-
matory mediators in the CNS, are key players in neu-
roinflammatory disorders. These cells contribute to both
pathogenic neurodegeneration and beneficial neuropro-
tection depending on how microglia interprets the threat
[3,4,41]. Therefore, it is crucial to identify the various
endogenous and exogenous factors that serve to activate
microglia, as well as the functional responses elicited by
them. In the present study we confirmed that exogenous
sPLA2-IIA induces microglial activation, evidenced by
increased cell proliferation, stimulation of their phagocytic
capabilities and robust production of inflammatory media-
tors such as COX-2 and TNFα. We used primary and
immortalized murine microglial cells with a defective Pla2
g2a gene, which makes them unable to produce sPLA2-
IIA [14], to exclude potential actions of the endogenous
phospholipase, since sPLA2-IIA may modulate different
cell functions depending on its cellular location [42]. In
addition, we demonstrated that sPLA2-IIA regulates func-
tions of activated microglia through EGFR transactivation
by induction of pro-HB-EGF processing via an ADAMs-
dependent mechanism. Moreover, ERK and mTOR are
key components of the intracellular signaling switch that
transduce EGFR activation into the aforementioned char-
acteristic of the activated microglia phenotype (Figure 9).
The importance of sPLA2-IIA in neurodegenerative
diseases, especially in those associated with inflamma-
tory processes has started to emerge in recent years.
Several studies have shown an increase in the expression
of sPLA2-IIA in reactive astrocytes both in experimental
models of cerebral ischemia and in specific regions of
human brains in AD associated with amyloid plaques
[11,12,18,23,26]. It has been suggested that the inter-
action of astrocytes with Aβ and other inflammatory
stimuli, such as IL-1β or TNFα, are responsible for
this sPLA2-IIA induction which could be associated in
the early inflammatory events. Although the ability
of sPLA2-IIA to affect the functional activities and the
survival or death of astrocytes, neurons and oligoden-
drocytes has been explored, this is the first study in
which the effect of sPLA2-IIA on microglial cells has
been addressed. Our interest in microglia owes to the
fact that these cells, in conjunction with astrocytes, are
responsible for coordinating inflammatory responses in
the brain and elicit immune responses against patho-
logical stimuli.
Several pro-inflammatory and immunoregulatory responses
associated with certain secreted PLA2 types have been
(See figure on previous page.)
Figure 5 Involvement of heparin-binding epidermal growth-like growth factor (HB-EGF) shedding in sPLA2-IIA-induced a proliferative
response. BV-2 cells were treated with the indicated inhibitors for 30 minutes at 37°C and then incubated with 1 μg/ml of sPLA2-IIA for 5
minutes. (A) HB-EGF expression was analyzed by flow cytometry: untreated cells (open black curves) were compared with sPLA2-IIA-treated
cells in the absence (open dark grey curves) or presence of the indicated inhibitors (open blue curves). Solid light grey curves show negative
controls in which the primary antibody was omitted. (B, C) BV-2 cells were incubated for 30 minutes at 37°C in the presence of the indicated
dose of an anti-HB-EGF neutralizing antibody, and then stimulated with 1 μg/ml of sPLA2-IIA. (B) After 15 minutes incubation, phosphorylation of
EGFR was analyzed by flow cytometry: untreated cells are represented by open black curves, whereas sPLA2-IIA-treated cells both in the absence
and in the presence of the neutralizing Ab are represented by open dark grey curves. Solid grey curves represent isotype controls. (C) After
15 minutes, whole cell lysates were extracted and protein phosphorylation was assessed by western blotting using p-ERK, p-P70S6, p-rS6 and
actin antibodies. Membranes also were stained with Ponceau S as a loading control. Results shown are representative of three independent
experiments. (D) Primary and immortalized BV-2 microglial cells were stimulated as indicated in the presence or absence of an anti-HB-EGF
neutralizing antibody. After 24 h, cell proliferation was investigated and expressed as optical density values ± SD. Values are the average of three
separate experiments in quadruplicate (*P< 0.001 compared to control cells, **P< 0.001 compared to sPLA2-IIA-stimulated cells).
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reported in previous studies. Thus, sPLA2-IIA induces
differentiation of monocytes into monocyte-derived den-
dritic cells or alternatively activated macrophages [36];
both human and bee venom type III trigger maturity of
dendritic cells, which is accompanied by up-regulation
of surface markers and by an increase in their migratory
and immunostimulatory capacity [43,44]. Furthermore,
type V regulates phagocytosis on macrophages by modu-
lating phagosome maturation [45]. sPLA2-IIA also
enhances the expression of COX-2 in mast cells and pro-
motes degranulation and cytokine release in human eosi-
nophils, as well as up-regulation of certain surface
activation markers [46]. In addition, sPLA2-IIA, IB,
X and III elicit proliferative signals, in vitro, in several
cell types [30,33,47-49], and type IIA has proven to be
protective even against oxysterol-induced apoptosis in
oligodendrocytes [50].
In this study we showed that sPLA2-IIA, as well as
type III, IB and V, enhance the proliferative and phago-
cytic capacity of BV-2 microglia cells to a similar extent
as IFNγ, one of the cytokines up-regulated in the brain
in different disorders and a well-known inducer of an
activated state in microglial cells. Focusing on type IIA
actions, two kind of phagocytosis have been evaluated:
phagocytosis of inert particles (as a measure of non-
specific phagocytosis) and of apoptotic cells (as a meas-
ure of disease-relevant processes of phagocytosis). The
ability of microglia to phagocytose inert material and
apoptotic cells is critical for the clearance of pathogen/
cell debris and dead cells under pathological conditions.
We demonstrated that sPLA2-IIA increases the uptake
of apoptotic Jurkat T cells as well as dextran beads, thus
indicating that sPLA2-IIA from the microenvironment
might contribute to the innate immune response on the
CNS by modulating the phagocytic efficiency of micro-
glial cells. These findings are in concordance with the
responses reported for other CNS soluble factors, in-
cluding IFNγ, as well as for various secreted sPLA2s on
other myeloid-lineage cells [36,43,44].
To our knowledge, there are no studies, either in vivo
or in vitro, describing production and secretion of sPLA2-
IIA by microglial cells, while astrocytes have been identi-
fied as a key cellular source of sPLA2-IIA in the CNS
under different pathological conditions [11,12,18,23,51].
Therefore, we propose that the sPLA2-IIA, once released
by astrocytes, might act on the microglia, in a paracrine
manner, to promote microglial activation and to further
stimulate phagocytosis and production of inflammatory
mediators such TNFα or COX-2 , thereby affecting the
inflammatory environment of the brain and contributing
to additional neuronal cell damage.
These results have led us to question the possible mechan-
isms - signaling molecules and receptors - underlying
the functional effects of sPLA2-IIA. It has previously
been reported that the biological activities induced by
sPLA2s can be dependent on both enzymatic and none-
nzymatic mechanisms. Whereas the ability of types X
and III to stimulate cell growth has been found to be
mostly dependent on their intrinsic catalytic activity,
the mitogenic response induced by type IB and IIA
seems to be unrelated to its enzymatic activity. Both an
integrin-dependent [30] and an EGFR-dependent path-
way [29] have been characterized as new sPLA2-IIA pu-
tative signaling mechanisms. In this study, we found that
sPLA2-IIA induced a phenotype of activated microglia in
BV-2 cells which is linked to the activation of the clas-
sical MAPK/ERK and mTOR/P70S6K pathways through
MMP-dependent ectodomain shedding of the transmem-
brane precursor pro-HB-EGF and subsequent transacti-
vation of the EGFR.
The EGFR is expressed ubiquitously in the mammalian
brain, being detected in neurons and glia cells [40,52]. It
has been hypothesized that EGFR activation is a master
signal transduction pathway of the cellular activation
process in response to different brain injuries and causes
the characteristics of the reactive astrocyte/microglia
phenotype [53-55]. Thus, activation of the EGFR path-
way is responsible for the hypertrophy, proliferation and
(See figure on previous page.)
Figure 6 sPLA2-IIA enhances phagocytosis on microglial cells. sPLA2-IIA induces fluorescein-isothiocyanate (FITC)-dextan beads uptake in
microglial cells. BV-2 microglial cells were treated with different doses of sPLA2-IIA and IFNγ (A), or with 1 μg/ml of different sPLA2 isoforms (B)
for 24 h at 37°C. Primary microglial cells were treated with 1 μg/ml of sPLA2-IIA and IFNγ (F). Then, cells were co-incubated with FITC-dextan
beads and quantified using a fluorescent plate reader, as detailed in Methods. Results are the average of three separate experiments in
quadruplicate and are expressed as the mean of the fluorescent intensity values ± SD (*P< 0.001 vs. control cells). (C) Images with a Leica TCS
SP5X confocal microscope, under a ×60 oil objective, confirm that fluorescent dextran associated with BV-2 microglia is internalized by the cells
and not only bound to the cell surface. (D) BV-2 cells were cultured in the absence or presence of 1 μg/ml of sPLA2-IIA or 100 UI/ml of IFNγ for
24 h at 37°C. Then, they were incubated with FITC-dextran for 1 h and analyzed by flow cytometry. Histograms represent one experiment out of
three. Solid grey curves represent unspecific endocytosis and open black curves endocytosis of cells cultured as indicated. (E, G) Primary and
immortalized BV-2 microglial cells were pretreated with the indicated inhibitors for 30 minutes. Cells were then treated with 1 μg/ml of sPLA2-IIA
at 37°C for 24 h followed by co-incubation with FITC-dextran for 30 minutes at 37°C. Phagocytosis was quantified using a fluorescent plate reader
as described under Methods. Values ± SD are the average of three separate experiments in quadruplicate (*P< 0.001 vs. control cells, **P< 0.001
compared to sPLA2-IIA stimulated cells).
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migration of reactive astrocytes, and perhaps of activated
microglia, at the site of neural injury [40,56,57]. We have
herein showed that sPLA2-IIA induces a sustained EGFR
phosphorylation at Tyr 1176 and Tyr 845 residues
that is abolished or diminished in the presence of the
selective EGFR inhibitor, AG1478. To understand the
mechanisms by which phospholipase causes EGFR phos-
phorylation, we used a general matrix metalloprotease
inhibitor (GM6001) and an ADAMs inhibitor (TAPI-1),
which are known to block the proteolytic cleavage of
various membrane-anchored EGFR pro-ligands such as
pro-EGF, pro-TGFα, pro-HB-EGF, and pro-amphiregulin.
We have found that the presence of these inhibitors
blocked the effect of sPLA2-IIA on EGFR phosphorylation
as well as on ectodomain shedding of HB-EGF, suggesting
a possible role of ADAMs and HB-EGF in sPLA2-IIA-
induced EGFR transactivation. Although it is possible that
other EGFR ligands could be also involved in sPLA2-IIA-
induced EGFR transactivation, the fact that the presence
of a HB-EGF-neutralizing Ab prevented the molecular
and biological effects of the phospholipase suggests that
HB-EGF plays a major role in the response induced by
the sPLA2-IIA. We focused mainly on HB-EGF because
of the extensive literature showing its role in cell survival
and proliferation, both in vivo and in vitro [58-61].
Whether the remnant C-terminal fragment generated,
HB-EGF-CTF, translocates to the nucleus and plays any
role in sPLA2-IIA signaling should be investigated in
greater detail in the future. Interestingly, transactivation
of EGFR upon microglial stimulation with IFNγ also
involves HB-EGF shedding, and is critical for the mito-
genic and pro-inflammatory activity of this cytokine. This
cross-talk mechanism between different signaling systems
allows the integration of the great diversity of stimuli and
supports the key role of the EGFR in diverse pathophysio-
logical disorders.
Additionally, we showed that sPLA2-IIA induces rapid
phosphorylation on Src at Tyr 416, and by using the
selective inhibitor PP2 we demonstrated that Src partici-
pates in both HB-EGF shedding and EGFR phosphoryl-
ation at Tyr 845 and at Tyr 1173. Likewise, as already
mentioned, EGFR phosphorylation at Tyr 845 (a Src
phosphorylation site) is also diminished by MMP inhibi-
tors, which indicates that products of MMPs are necessary
for Src-mediated phosphorylation of EGFR at Tyr-845.
Thus, it raises the possibility that EGFR ligands generated
by MMP-mediated cleavage of membrane precursors col-
laborate with Src kinases in promoting sPLA2-IIA-induced
EGFR transactivation. Therefore, our results suggest that
Src contributes to sPLA2-IIA-induced EGFR transactiva-
tion at various steps: Src may serve as an upstream com-
ponent of EGFR transactivation by phosphorylating Tyr
845 directly and indirectly by a MMPs/ADAMs/HB-
EGF-dependent mechanism. These findings are consist-
ent with abundant evidence indicating that external
stimuli can transactivate EGFR in complex Src-
dependent signaling [62-64]. Further studies are required
to clarify the precise role of Src in this system, as well as
to determine which member(s) of the family (Src, Fyn,
and Yes) is involved in sPLA2-IIA-induced EGFR trans-
activation and BV-2 cells activation. It is possible that a
particular member is involved in HB-EGF shedding and
another one in EGFR phosphorylation at Tyr 845.
In contrast to Src signaling, sPLA2-IIA-activated
MEK/ERK/MAPK and mTOR/P70S6K signaling path-
ways effectively seem to be downstream of EGFR trans-
activation. Thus, whereas the experimental conditions
that affect HB-EGF release and EGFR phosphorylation
abrogate phosphorylation of ERK, P70S6K and rS6, the
presence of the specific inhibitors PD98059 (for MEK),
or rapamicin (for mTOR) scarcely affects sPLA2-IIA-
stimulated HB-EGF shedding and EGFR phosphoryl-
ation. In addition, our data suggest a complex, not
linear, signaling network involving these two cascades, as
the inhibition of any of those pathways prevents sPLA2-
IIA-promoted activation of BV-2 microglia cells. It has
been described that both pathways cross-talk extensively
and may regulate each other both positively and nega-
tively [65]. mTOR can be considered a key node of these
complex signaling cascades, and exists as two different
entities: the raptor-mTOR complex and the rictor-
mTOR complex. Thus, it has been reported that
(See figure on previous page.)
Figure 7 sPLA2-IIA induces efferocytosis in BV-2 cells. BV-2 cells were treated with 1 μg/ml of sPLA2-IIA or 100 UI/ml IFNγ for 24 h at 37°C,
exposed to PrI-labelled apoptotic Jurkat cells for 2 h, and then stained with an anti-PE-CD68 antibody, as described under Methods. (A)
Phagocytosis was analyzed by flow cytometry. FL2 fluorescence (left) shows BV-2 cells expressing CD68. The bar marks the population of BV-2
cells which was gated for detection of PrI-apoptotic cell uptake. FL3 fluorescence (right) shows the red fluorescence (PrI-apoptotic cells) in
PE-CD68-labelled cells (on the gated BV-2 cells). As a measure of the phagocytosed cells, MIF values are shown. (B) Phagocytosis was also studied
by confocal microscopy (final magnification ×60). Co-cultures of PrI-apoptotic cells with either resting or stimulated BV-2 cells were fixed and
stained with Alexa-fluor-CD11b and DAPI. Laser confocal images confirm that fluorescent apoptotic cells associated with BV-2 microglia are
internalized by the cells and not only bound to the cell surface. (C) Confocal images with reconstructed orthogonal projections presented as
viewed in the x-z plane (bottom) and y-z plane (right): Fluorescent apoptotic cells (stained with PrI) are shown to be internalized by BV-2
microglia. (DAPI-labelled nuclei, blue). Scale bars: 10 μm in sPLA2-treated cells, and 7.5 μm in IFNγ-treated cells. (D) BV-2 cells were treated with
the indicated inhibitor for 30 minutes before sPLA2-IIA stimulation and mixing with the apoptotic cells. Phagocytosis was analyzed as in (A). In all
the histograms, the solid grey curve represent the resting/control cells. The results are representative of three independent experiments.
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phosporylation of P70S6K and its substrate, rS6, can take
place in a rapamycin-dependent manner [66,67], or inde-
pendently of mTOR, being Akt, ERK and even phospha-
tidic acid, direct upstream effector molecules [68,69].
Moreover, inhibition of the raptor-mTOR complex
can trigger activation of the ERK/MAPK cascade, while
inhibition of the rictor-mTOR complex inhibits Akt and
ERK phosphorylation [70]. We have found that rapamy-
cin, as well as PD98059, at concentrations that diminish
or even suppress the proliferative and fagocytic capabil-
ities of sPLA2-IIA-activated BV-2 cells, also suppress
phosphorylation of ERK, P70S6K and rS6. In this study
there was no attempt to investigate more deeply the
effect of sPLA2-IIA on the sequential activation of these
Figure 8 sPLA2-IIA exhibits pro-inflammatory actions by stimulating TNFα and cycloxygenase-2 (COX-2) protein expression. BV-2
microglial cells were incubated with 1 μg/ml of sPLA2-IIA or 100 UI/ml IFNγ at 37°C. (A) After 4 and 8 h of stimulation, COX-2 expression was
identified in the cell lysated by western blot. Membranes were also stained with Ponceau S as a loading control. (B) After 24 h, the presence
of TNFα in the cell culture medium was quantified by commercial ELISA. In some experiments, COX-2 expression (C) and TNFα secretion (D) was
evaluated from cells pretreated with the indicated inhibitors. Results shown are representative of three independent experiments. (*P< 0.001 vs.
control cells, **P< 0.001 vs. sPLA2-IIA-treated cells).
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signaling proteins or the cross-talk between the raptor-
mTOR/rictor-mTOR complexes. However, the relation-
ship between these signaling pathways certainly deserves
further, independent study due to the complex link exist-
ing between their components.
Conclusions
In conclusion, our results reveal that sPLA2-IIA activates
primary and immortalized BV-2 microglia cells; EGFR
plays a key role as a critical regulator of this sPLA2-IIA-
mediated effect, and also indicates that shedding of pro-
HB-EGF is a crucial step in this response. Accordingly,
the possibility that sPLA2-IIA may affect immune system
function in the CNS in certain pathologies should be
carefully considered.
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